使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Ladies and gentlemen, thank you for standing by for So-Young's second-quarter 2026 earnings conference call. (Operator Instructions) As a reminder, today's conference call is being recorded.
各位女士、先生,感謝您撥冗參加(並保持在線)So-Young 2026 年第二季度業績電話會議。(接線員指示) 提醒各位,今天的電話會議將被錄音。
I would now like to turn the meeting over to your host for today's call, Ms. Mona Qiao. Please proceed, Mona.
現在我想把會議交給今天電話會議的主持人 Mona Qiao 女士。Mona,請開始。
Mona Qiao - Investor Relations Contact
Mona Qiao - Investor Relations Contact
Thank you, operator, and thank you, everyone, for joining So-Young's second-quarter 2026 earnings conference call. Joining the call today are Mr. Xing Jin, our Founder, Chairman and CEO; and Ms. Shannon Shen, our CFO.
謝謝接線員,也謝謝各位參加 So-Young 2026 年第二季度業績電話會議。今天與會的有我們的創辦人、董事長兼執行長金星先生,以及我們的財務長 Shannon Shen 女士。
Before we begin, please refer to the Safe Harbor statement in our earnings release, which applies to this call as we will be making forward-looking statements. We will also discuss non-GAAP financial measures. Reconciliations between GAAP and non-GAAP measures are included in today's earnings press release.
在開始之前,請參閱我們業績新聞稿中的「安全港」聲明;由於我們將在本次電話會議中發表前瞻性陳述,該聲明同樣適用於本次會議。我們也將討論非 GAAP 財務衡量指標。GAAP 與非 GAAP 指標之間的調節表已包含在今天的業績新聞稿中。
Please also note, all figures mentioned in this call are in RMB unless otherwise stated. With that, I'd like to turn the call over to Mr. Xing Jin.
另請注意,除非另有說明,本次電話會議中提及的所有數據均以人民幣計。接下來,我想把電話交給金星先生。
Xing Jin - Chairman of the Board, Chief Executive Officer, Chief Financial Officer, Co-Founder
Xing Jin - Chairman of the Board, Chief Executive Officer, Chief Financial Officer, Co-Founder
(interpreted) Hello, everyone, and welcome to today's earnings call. In Q2 2026, we continue to expand our Aesthetic Treatment business, guided by our dual engine of scale and efficiency, backed by our ever-improving medical capabilities, a uniform delivery framework and wider AI adoption. The business enhanced its operational ability and delivered a robust performance.
(口譯) 各位好,歡迎參加今天的業績電話會議。在 2026 年第二季度,我們在規模與效率的雙引擎驅動下,持續擴展我們的醫美治療業務;並以不斷提升的醫療能力、統一的交付框架以及更廣泛的 AI 應用作為支撐。該業務提升了營運能力,並交出強勁表現。
Its Q2 revenue reached RMB330 million, up roughly 130% year over year, beating the upper end of guidance by about 5%. As a result, group revenue achieved a quarterly record, growing 33% year over year to about RMB510 million (sic - see press release, "RMB505.2 million"). With better operating efficiency, net loss attributable to the company narrowed by 37% year over year to RMB22.7 million.
第二季度營收達到人民幣 3.30 億元,同比增長約 130%,較指引上限高出約 5%。因此,集團營收創下單季新高,同比增長 33% 至約人民幣 5.10 億元(原文 sic - 見新聞稿「人民幣 5.052 億元」)。隨著營運效率提升,歸屬於公司的淨虧損同比收窄 37% 至人民幣 2,270 萬元。
Now turning to the key business developments in Q2. The dual-engine approach delivered clear results this quarter. So-Young clinic kept a healthy pace of expansion while operating quality improved. By the end of Q2, So-Young clinic expanded into 18 cities with 65 centers in total. The larger footprint improved accessibility. More importantly, it reinforced brand awareness and captured consumer market share, driving continued growth in treatment volume and user base.
接下來談談第二季度的關鍵業務進展。本季度雙引擎策略取得了清晰成果。So-Young 診所保持健康的擴張節奏,同時營運品質也有所提升。截至第二季度末,So-Young 診所已進入 18 個城市,合計 65 家中心。更大的佈局提升了可及性。更重要的是,它強化了品牌認知並獲取消費者市場份額,推動治療量與用戶基礎持續增長。
On treatment volume, verified visit exceeded 165,000 in Q2, up 145% year over year. Verified Aesthetic Treatment performed were above 362,000, up 134% year over year. On the user front, active users reached over 250,000 (sic - see press release, "255,000") by the end of June. In particular, the number of level three and above core members exceeded 78,000.
在治療量方面,第二季度核驗到診(verified visit)超過 16.5 萬人次,同比增長 145%。核驗完成的醫美治療(Verified Aesthetic Treatment performed)超過 36.2 萬例,同比增長 134%。在用戶方面,截至 6 月底,活躍用戶超過 25 萬(原文 sic - 見新聞稿「25.5 萬」)。其中,三級及以上核心會員數量超過 7.8 萬。
The quarterly rate of core members remained robust, reflecting high user regard for our quality. New customers count also grew quarter over quarter with over 50% of them being referrals. This lowered blended acquisition costs while building a loyal, high-quality user base, which in turn positions us to boost user LTV and retention.
核心會員的季度留存率保持強勁,反映用戶對我們品質的高度認可。新客數量亦環比增長,其中超過 50% 來自轉介紹。這降低了綜合獲客成本,同時建立忠誠且高品質的用戶基礎,進而使我們能提升用戶 LTV(終身價值)與留存。
Meanwhile, both the volume and mix of public domain new customers rose, confirming that our full channel acquisition playbook works. The profitability of the store also improved as we refined operating workflows and tightened resource coordination.
同時,公域新客的規模與結構均有所提升,印證我們全渠道獲客打法行之有效。隨著我們優化營運流程並加強資源協同,門店盈利能力也有所改善。
As a result, in Q2, the number of profit centers rose to 47 with 51 generating positive operating cash flow. Gross margin of the Aesthetic Treatment business improved by about 3.8 percentage points year over year to 28.1%. This outcome validates our management approach.
因此,在第二季度,盈利中心數量提升至 47 個,其中 51 個實現正向經營性現金流。醫美治療業務的毛利率同比提升約 3.8 個百分點至 28.1%。這一結果驗證了我們的管理方法。
Healthy growth of our Aesthetic Treatment business relies on a robust supply chain and enriched product lineup. In late April, Miracle Collagen, our joint product with Jinbo Biopharmaceuticals, launched to a warm reception with over 66,000 units sold to date.
我們醫美治療業務的健康增長,依賴於穩健的供應鏈與更豐富的產品組合。4 月下旬,我們與錦波生物製藥聯合推出的產品 Miracle Collagen 上市後反響熱烈,截至目前已售出超過 6.6 萬支。
In June, we rolled out [WeMed CoPack]. It adopts self-cross-linking technology to create a gel texture without a cross-linking agent. WeMed CoPack helps build eye and face areas while promoting ongoing collagen regeneration for a natural look. Our partnership with Jinbo goes beyond a traditional buyer and vendor relationship. It is a move towards product co-creation, case development and long-term value alignment.
6 月,我們推出了[WeMed CoPack]。該產品採用自交聯技術,在不使用交聯劑的情況下形成凝膠質地。WeMed CoPack 有助於塑造眼周與面部區域,同時促進持續的膠原再生,呈現自然效果。我們與錦波的合作不僅是傳統的買方與供應商關係。這是朝向產品共創、案例開發與長期價值對齊的舉措。
Going forward, we plan to extend this model to more domestic and international medical device and treatment partners. This collaboration model will cover consumer insights, product definition, indication development, physician training, uniform protocols, post-launch evaluation and continuous intervention, bringing advanced technology from R&D to real-world use at a faster pace.
展望未來,我們計劃將該模式延伸至更多國內外醫療器械與治療合作夥伴。此合作模式將涵蓋消費者洞察、產品定義、適應症開發、醫師培訓、統一操作規範、上市後評估與持續干預,使先進技術能以更快速度從研發走向真實世界應用。
Also introduced beauty version of Miracle PLLA. It uses a better calibrated PLLA microparticle diameter to improve injection outcomes. Beyond the collagen category, we are also expanding the product portfolio to meet diverse anti-aging demand.
我們也推出了 Miracle PLLA 的美容版本。其採用更精準校準的 PLLA 微粒粒徑,以改善注射效果。除膠原品類外,我們也在擴充產品組合,以滿足多元的抗衰老需求。
Furthermore, we continued to enhance our uniform medical delivery capabilities. First, we expand our physician team to meet growing market demand. As of June 30, 2026, the number of full-time physicians increased to around 280.
此外,我們持續提升統一的醫療交付能力。首先,我們擴充醫師團隊以滿足不斷增長的市場需求。截至 2026 年 6 月 30 日,全職醫師人數增至約 280 人。
On top of that, we have kept physician capabilities and treatment workflows aligned. This is made possible by our medical R&D and training center treatment guidelines, video audits and other training and quality control mechanisms we have in place.
在此基礎上,我們持續保持醫師能力與治療流程的一致性。這得益於我們醫療研發與培訓中心制定的治療指引、影片稽核,以及其他已建立的培訓與品質管控機制。
In Q2, we partnered with leading upstream manufacturers, including Allergan and Jinbo to deliver nine specialized training workshops, effectively enhancing our physicians' expertise and clinical skills. We also completed 12 regular training sessions as part of our new physician initiative.
第二季度,我們與包括 Allergan 與錦波在內的上游領先製造商合作,開展了 9 場專項培訓工作坊,有效提升了醫師的專業能力與臨床技能。我們也完成了 12 場常規培訓,作為新醫師培育計畫的一部分。
By assessing theoretical knowledge and hands-on skills, we ensure our newly onboarded physicians are well prepared to deliver uniform and safe clinical care. Additionally, build a national command and control center, we coordinate medical workflows end-to-end to further elevate the user experience.
透過對理論知識與實操技能的評估,我們確保新加入的醫師已充分準備好提供一致且安全的臨床照護。此外,建立全國指揮與控制中心,我們端到端協調醫療工作流程,以進一步提升用戶體驗。
Finally, we are integrating AI with medical aesthetics to unlock innovative test for expansion. Under the constraints of medical safety, user privacy, and data compliance, we believe AI's core value lies in empowering physicians, keeping delivery quality consistent and breaking the industry's ceiling on scale. This approach will ultimately bring premium medical care for more consumers.
最後,我們正將 AI 與醫療美容結合,以開啟創新的測試並推動擴張。在醫療安全、使用者隱私與資料合規的約束下,我們相信 AI 的核心價值在於賦能醫師、確保交付品質一致,並突破產業在規模上的天花板。此一作法最終將讓更多消費者享有高品質的醫療照護。
Right now, our focus is on the data foundation, which powers service quality, user experience and upstream R&D enablement. Leveraging our years of industry data and capabilities across med platform, user operations and clinical practices, we are now building a real-world database and clinical AI infrastructure tailored for the industry. For example, our clinics launched a user-facing virtual medical dispensing platform and dual screens that treatment SOPs in real time, both have effectively boosted user trust.
目前,我們的重點在於資料基礎建設,這將驅動服務品質、使用者體驗以及上游研發賦能。憑藉我們多年累積的產業資料,以及在醫美平台、使用者營運與臨床實務方面的能力,我們正在打造一套為產業量身定制的真實世界資料庫與臨床 AI 基礎設施。例如,我們的診所推出面向使用者的虛擬醫療配藥平台,以及可即時顯示治療 SOP 的雙螢幕,兩者皆有效提升了使用者信任。
Looking ahead, the principles of transparency, uniform delivery and accessibility will continue to guide us. We remain focused on building a premium medical service framework and deepening customer trust. We believe that as we expand ongoing refinement of our operating framework, we will drive continued gains in operating efficiency and margins.
展望未來,透明、交付一致性與可及性等原則將持續指引我們。我們仍將專注於打造高品質醫療服務框架並深化客戶信任。我們相信,隨著我們在擴張過程中持續精進營運框架,將推動營運效率與利潤率的持續提升。
This will unlock greater economics of scale across our clinic chain. Meanwhile, we will further diversify our supply chain, advance AI-powered digital capabilities and deliver a more competitive product portfolio. We are confident that these initiatives will drive high-quality growth for our Aesthetic Treatment business.
這將在我們的診所連鎖體系中釋放更強的規模經濟效益。同時,我們將進一步多元化供應鏈、推進 AI 驅動的數位能力,並提供更具競爭力的產品組合。我們有信心,這些舉措將推動我們醫美治療業務的高品質成長。
Now I will hand over to our CFO, Shannon Shen, for a deep dive into Q2 financials, after which we will move to Q&A session.
接下來我將把時間交給我們的財務長 Shannon Shen,深入解讀 2026 年第二季財務表現,之後我們將進入問答環節。
Shannon Shen - Chief Financial Officer
Shannon Shen - Chief Financial Officer
Thank you, Qiao, and thank you, everyone, for joining our call today. It's my great pleasure to walk you through So-Young's second-quarter 2026 performance. On behalf of the management team, I will now share with you our latest operational progress across three key dimensions: growth, efficiency and organizational effectiveness. Please note that all financial data will be presented in RMB terms, unless otherwise noted.
謝謝你,Qiao,也謝謝各位今天參與我們的電話會議。我很高興帶各位回顧新氧(So-Young)2026 年第二季的表現。我將代表管理團隊,與各位分享我們在三個關鍵面向的最新營運進展:成長、效率與組織效能。請注意,除非另有說明,所有財務數據均以人民幣呈列。
First, in the second quarter of 2026, our Aesthetic Treatment business exceeded RMB330 million in revenue, growing approximately 130% year over year and marking its 10th consecutive quarter of triple-digit year-over-year revenue growth. Not only has this propelled our total revenues to an all-time high with a 33% year-over-year increase, but it has also enabled our Aesthetic Treatment business to achieve favorable economics of scale.
首先,在 2026 年第二季,我們的醫美治療業務營收超過人民幣 3.3 億元,年增約 130%,並連續第 10 個季度實現三位數的年增營收成長。這不僅推動我們總營收創下歷史新高、年增 33%,也使我們的醫美治療業務實現了有利的規模經濟效益。
Behind this clear upward growth trajectory and our rising brand momentum is our scaled capacity to deliver high-quality products and services. For digital natives, we offer wonderful product value that aligns with their consumption patterns, aesthetic preferences and online purchasing habits, thereby driving sustainable growth characterized by high frequency and high retention.
支撐這一明確上行的成長軌跡與品牌動能提升的,是我們已具規模的高品質產品與服務交付能力。針對數位原生族群,我們提供與其消費模式、審美偏好與線上購買習慣相契合的優質產品價值,從而帶動以高頻次與高留存為特徵的可持續成長。
While sustaining rapid top-line growth, we remain unwavering in our commitment to growth quality and long-term sustainability with a laser focus on strengthening unit economics. We recently have raised our aesthetic centers capacity utilization benchmark by 50%, reflecting elevated expectations for per store revenue, labor productivity and sales per square meter.
在維持營收端快速成長的同時,我們對成長品質與長期可持續性始終堅定不移,並高度聚焦於強化單位經濟效益。我們近期將醫美中心的產能利用率基準提高了 50%,反映出我們對單店營收、人力生產力與每平方米銷售額的更高期待。
Through operational excellence, streamlining customer flow to reduce redundant waiting period, optimizing dynamic staffing, leveraging intelligent inventory management, we expect to drive meaningful margin expansion at aesthetic centers. Going forward, our expansion strategy will be more disciplined and market responsive.
透過卓越營運、精簡客流以降低重複等待時間、優化動態排班,以及運用智慧庫存管理,我們預期將推動醫美中心利潤率的顯著擴張。展望未來,我們的擴張策略將更具紀律並更能回應市場。
We will dynamically calibrate our opening cadence based on regional utilization levels, enabling us to sustain high revenue growth while striking an optimal balance between scale and profitability. We prioritize sustainable growth over pure top-line expansion. In the second quarter of 2026, we delivered a 37% year-over-year improvement in profitability.
我們將依據各區域的利用率水準動態校準開店節奏,使我們在維持高營收成長的同時,在規模與獲利之間取得最佳平衡。相較於單純追求營收規模擴張,我們更重視可持續成長。在 2026 年第二季,我們的獲利能力年增提升 37%。
Rapid expansion places extraordinary demand on organizational capabilities. Best-in-class organizational excellence is fundamental to sustaining high growth over the long term. To that end, we have made systematic investments in organizational infrastructure with a particular focus on compliance and user experience.
快速擴張對組織能力提出了極高要求。一流的組織卓越是長期維持高速成長的基礎。為此,我們對組織基礎設施進行了系統性投入,特別聚焦於合規與使用者體驗。
We continue to advance end-to-end visibility across treatment workflows to enhance transparency and reinforce trust. Furthermore, we have closed the loop on user feedback. This cross-functional coordination enables us to maintain acute market sensitivity and continuously elevate service delivery quality and user satisfaction even as the business scales rapidly.
我們持續推進治療工作流程的端到端可視化,以提升透明度並強化信任。此外,我們已完成使用者回饋的閉環管理。這種跨部門協同使我們即便在業務快速擴張之際,仍能保持敏銳的市場洞察,並持續提升服務交付品質與使用者滿意度。
The company stands at a pivotal inflection point, pursuing high growth and operational efficiency in parallel, while advancing scale and profitability in lock step. 10 consecutive quarters of triple-digit revenue growth validate our market acumen and execution discipline.
公司正處於關鍵拐點,在追求高速成長與營運效率並行的同時,推動規模與獲利同步提升。連續 10 個季度的三位數營收成長,驗證了我們的市場洞察力與執行紀律。
This continuous refinement of center-level unit economics, together with our market responsive expansion strategy, ensures that our growth remains high quality and sustainable. Complementing this, our systematic investments in organizational capabilities provide the bedrock for long-term value creation.
持續精進中心層級的單位經濟效益,結合我們以市場為導向的擴張策略,確保我們的成長維持高品質且可持續。與此相輔相成的是,我們對組織能力的系統性投入,為長期價值創造奠定了堅實基礎。
Next, let's dive into each business segment. Revenues from Aesthetic Treatment services reached RMB331.4 million, exceeding the upper end of guidance for the sixth consecutive quarter. The rollout of our loyalty program and systematic treatment protocols creates a 3 to 5 percentage points deferral between service delivery and recognized accounting revenue.
接下來,我們深入各業務分部。醫美治療服務營收達人民幣 3.314 億元,連續第六個季度超過指引上限。我們忠誠度計畫的推行與系統化治療流程,導致服務交付與會計認列營收之間出現 3 至 5 個百分點的遞延。
Today's service generated future membership benefits. While this tempers near-term reported revenue, it builds a deferred revenue base that underpins long-term growth. Net of this deferral impact, revenue still grew approximately 103%.
今日提供的服務將產生未來的會員權益。雖然這會抑制短期的報表營收,但也建立了遞延收入基礎,支撐長期成長。扣除此遞延影響後,營收仍年增約 103%。
Looking at aesthetic centers data as of June 30, we operated 65 So-Young clinics across 18 major cities, reflecting a net addition of 11 centers during the quarter. Among them, 47 centers were profitable and 51 centers generated positive operating cash flow during the quarter, reflecting a net addition of 6 and 3, respectively, from last quarter. We also achieved same-store sales growth of 52%, substantially improved from 14% in the prior year period.
截至 6 月 30 日的醫美中心數據顯示,我們在 18 個主要城市共營運 65 家新氧診所,本季度淨新增 11 家中心。其中,47 家中心實現獲利,51 家中心在本季度產生正向營運現金流,較上季度分別淨增加 6 家與 3 家。我們亦實現同店銷售成長 52%,較去年同期的 14% 大幅提升。
Turning to our other segments. Revenues from Information and Reservation services were RMB87.9 million, down 35% year over year, primarily due to the decrease in the number of medical service providers subscribing to our information services.
接著看我們的其他業務分部。資訊與預約服務營收為人民幣 8,790 萬元,年減 35%,主要由於訂閱我們資訊服務的醫療服務提供者數量下降。
Sales of Medical Products and Maintenance services revenues were RMB73.9 million, down 2.8% year over year, primarily due to the decrease in order volume for medical equipment. Other services revenues were RMB12 million, down 48.2% year over year due to a lower insurance brokerage revenue.
醫療產品銷售及維護服務營收為人民幣 7,390 萬元,年減 2.8%,主要由於醫療設備訂單量下降。其他服務營收為人民幣 1,200 萬元,年減 48.2%,原因是保險經紀收入較低。
Cost of revenues was RMB282.4 million, up 53% year over year, driven primarily by the expansion of our branded aesthetic centers. Total operating expenses were RMB266.5 million, up 10.4% year over year. Specifically, sales and marketing expenses were RMB153.5 million.
營收成本為人民幣2.824億元,同比增長53%,主要受我們自有品牌醫美中心擴張所帶動。總營運費用為人民幣2.665億元,同比增長10.4%。具體而言,銷售及行銷費用為人民幣1.535億元。
From Aesthetic Treatment service perspective, our comprehensive customer acquisition cost remains at a healthy level, accounting for less than 10% of the revenue. Coupled with strong user retention, our overall customer acquisition model maintains sustainable.
從醫美治療服務角度來看,我們的綜合獲客成本仍維持在健康水準,占收入比例低於10%。在強勁的用戶留存加持下,我們整體獲客模式保持可持續性。
G&A expenses were RMB88.6 million, up 12.5% year over year, reflecting the continued expansion of our branded aesthetic centers. R&D expenses were RMB24.4 million, down 21.7% year over year, driven by continued improvements in staff efficiency.
一般及行政(G&A)費用為人民幣8,860萬元,同比增長12.5%,反映我們自有品牌醫美中心的持續擴張。研發(R&D)費用為人民幣2,440萬元,同比下降21.7%,主要由於員工效率持續提升。
Moving forward, we will continue to deepen AI integration across our operations, streamlining workflows and driving efficiency gains in R&D, clinical diagnosis and treatment and beyond. Income tax benefits were RMB2.5 million compared with income tax expenses of RMB1.9 million in the prior year period.
展望未來,我們將持續深化AI在各項營運中的整合,精簡工作流程,並推動研發、臨床診斷與治療等領域的效率提升。所得稅利益為人民幣250萬元,而去年同期為所得稅費用人民幣190萬元。
Net loss attributable to So-Young was RMB22.7 million, which narrowed by 37% compared with RMB36 million in the prior year period. Non-GAAP net loss attributable to So-Young was RMB21 million compared with RMB30.5 million in the prior year period.
歸屬於新氧的淨虧損為人民幣2,270萬元,較去年同期人民幣3,600萬元收窄37%。歸屬於新氧的非GAAP淨虧損為人民幣2,100萬元,而去年同期為人民幣3,050萬元。
Basic and diluted loss per ADS were both RMB0.22 compared with RMB0.35 in the prior year period. As of June 30, 2026, our cash and cash equivalents, restricted cash and term deposits and short-term investments totaled RMB848.2 million.
每股ADS基本及攤薄虧損均為人民幣0.22元,而去年同期為人民幣0.35元。截至2026年6月30日,我們的現金及現金等價物、受限制現金、定期存款及短期投資合計為人民幣8.482億元。
Turning to our outlook. Please allow me to remind everyone that this contains forward-looking statements, which include risks and uncertainties that are beyond our control and could cause the actual results to differ materially from our predictions. Based on our current estimates, we expect revenues from Aesthetic Treatment services to be between RMB352 million and RMB362 million, representing year-over-year growth of 91.7% to 97.2%.
接下來談談我們的展望。請允許我提醒各位,以下內容包含前瞻性陳述,其中包含超出我們控制範圍的風險與不確定性,可能導致實際結果與我們的預測存在重大差異。基於我們目前的估計,我們預期醫美治療服務收入將介於人民幣3.52億元至3.62億元之間,代表同比增長91.7%至97.2%。
That concludes my prepared remarks. Operator, we are now ready for the Q&A session. Thanks.
以上為我準備的發言。接線員,我們現在準備進入問答環節。謝謝。
Operator
Operator
(Operator Instructions) Jinpeng He, CITIC.
(接線員指示) 何金鵬,中信。
Jinpeng He - Analyst
Jinpeng He - Analyst
(interpreted) Firstly, congratulations on the company's continued strong performance and impressive growth in the second quarter. So I have a question regarding the collaboration with Jinbo. So the collaboration is generating great momentum with innovative partnership model. So what have both parties liked and what are the benefits?
(口譯) 首先,恭喜公司在第二季持續保持強勁表現並實現亮眼增長。我有一個關於與錦波合作的問題。這項合作透過創新的合作模式帶來了很強的動能。雙方各自看重的是什麼?帶來了哪些益處?
Xing Jin - Chairman of the Board, Chief Executive Officer, Chief Financial Officer, Co-Founder
Xing Jin - Chairman of the Board, Chief Executive Officer, Chief Financial Officer, Co-Founder
(interpreted) We are pleased to have reached a reliable mutually beneficial partnership with Jinbo as medical aesthetic demand moves towards natural restoration, tissue regeneration and long-lasting outcomes. The component humanized collagen will have a long lifespan. A developing upstream relationship with Jinbo, therefore, benefits our long-term growth.
(口譯) 隨著醫美需求朝向自然修復、組織再生與持久效果演進,我們很高興與錦波建立了可靠且互利的合作夥伴關係。其中,人源化膠原蛋白成分具有較長的生命週期。因此,與錦波建立上游合作關係,有利於我們的長期成長。
More importantly, we are using real-world data to drive product and supply chain decisions. We analyze connections between user age, skin condition, treatment details, post-treatment reaction, feedback and repurchasing behavior. From there, we can pinpoint which products, which population area and treatment combination.
更重要的是,我們正使用真實世界數據(real-world data)來驅動產品與供應鏈決策。我們分析用戶年齡、皮膚狀況、治療細節、術後反應、回饋與復購行為之間的關聯。基於此,我們可以精準定位哪些產品、哪些人群區域以及治療組合。
This helped us optimize doctor training, program decision and inventory planning, which greatly reduces buying guesswork and excess inventory. It also lets upstream manufacturers move out of a closed R&D environment and integrate their products based on actual clinical insights. This enhances our operational efficiency and leverage in joint research, product innovation and partnership.
這幫助我們優化醫師培訓、方案決策與庫存規劃,大幅降低採購猜測與庫存過剩。同時也讓上游製造商走出封閉的研發環境,基於實際臨床洞察來整合其產品。這提升了我們在聯合研究、產品創新與合作夥伴關係方面的營運效率與議價能力。
Going forward, we will extend this data feedback co-creation model to more quality partners at home and abroad. In the past, many viewed downstream clinics only as distribution channels. Today, we are transforming our extensive clinic network into the industry's innovation infrastructure.
展望未來,我們將把這一數據回饋共創模式延伸至更多國內外優質合作夥伴。過去,許多人將下游診所僅視為分銷渠道。如今,我們正把廣泛的診所網絡轉型為行業的創新基礎設施。
By leveraging real-world consumer demand, hands-on experience and treatment outcomes to deliver R&D, we aim to accelerate technology innovation and product integration, ultimately delivering value to more consumers.
透過運用真實世界的消費者需求、第一手經驗與治療結果來反哺研發,我們希望加速技術創新與產品整合,最終為更多消費者創造價值。
Operator
Operator
James Wang, GF Securities.
王詹姆斯,廣發證券。
James Wang - Analyst
James Wang - Analyst
(interpreted) This is James Wang, GF Securities. Congratulations on the outstanding performance. Management mentioned a few AI initiatives. Could you elaborate more on how AI is being applied in the business? Where do you see the biggest value and future direction?
(口譯) 我是廣發證券的王詹姆斯。恭喜取得出色的業績表現。管理層提到了一些AI相關舉措。能否更詳細說明AI在業務中的應用方式?您認為最大的價值點與未來方向在哪裡?
Xing Jin - Chairman of the Board, Chief Executive Officer, Chief Financial Officer, Co-Founder
Xing Jin - Chairman of the Board, Chief Executive Officer, Chief Financial Officer, Co-Founder
(interpreted) Medical aesthetics is a highly medical field with a low tolerance for error. It relies heavily on individual expertise. The core value of AI lies in transforming experience-driven, hard-to-reproduce procedures into uniform, visible, and traceable offerings. This approach also helps distribute premium medical resources to lower-tiered cities, which helps address imbalances in medical delivery.
(口譯) 醫美是一個高度醫療化、對錯誤容忍度很低的領域。它高度依賴個人專業能力。AI的核心價值在於,將依賴經驗、難以複製的流程,轉化為標準化、可視化且可追溯的服務。這一方式也有助於把優質醫療資源下沉至低線城市,從而緩解醫療供給不均衡問題。
In practice, our current focus is applying AI to product authentication, back-office quality control and data foundations and governance. QR code authentication verifies medicine and device traceability immediately, mitigating counterfeit-related concerns and building trust. End-to-end transparency builds the users' confidence in care and overall experience.
在實務層面,我們目前的重點是將AI應用於產品驗真、後台品質管控,以及數據底座與治理。透過二維碼驗真可即時核驗藥品與器械的可追溯性,降低對假貨的疑慮並建立信任。端到端的透明度提升了用戶對醫療照護與整體體驗的信心。
We also use AI to break down top physicians' experience into database. We then embedded it into our SOPs, case libraries and post-treatment feedback modules. That accelerates new physicians' development, aligns quality across centers and identifies irregularities in real time, lifting overall quality and customer experience.
我們也使用AI將頂尖醫師的經驗拆解並沉澱到資料庫中。隨後把它嵌入到我們的SOP、案例庫與術後回饋模組。這能加速新醫師成長、在各中心之間對齊品質,並即時識別異常,從而提升整體品質與客戶體驗。
In Q4 this year, we will roll out our first generation of fully intelligent centers, initiating widespread AI deployment across our network. We aim to replicate our high-quality medical delivery and operating capabilities via AI. Given our industry leadership and early mover advantage in digital infrastructure, we are confident that driven by AI, we can lead the industry into a new phase of high-quality growth.
在今年第四季,我們將推出第一代全智能中心,啟動在整個網絡的廣泛AI部署。我們希望透過AI複製我們高品質的醫療交付與營運能力。憑藉我們在行業中的領先地位以及在數位基礎設施方面的先發優勢,我們有信心在AI驅動下,引領行業進入高品質成長的新階段。
Operator
Operator
Nelson Cheung, Citibank.
張納爾遜,花旗銀行。
Nelson Cheung - Analyst
Nelson Cheung - Analyst
(interpreted) We observed that the aesthetic center gross margin has improved this quarter. Would you walk through what are the key drivers for the improvement? And what are your future plans for gross margin expansion in the future?
(口譯) 我們觀察到本季醫美中心的毛利率有所改善。能否請您說明毛利率改善的關鍵驅動因素是什麼?以及未來在毛利率擴張方面有何規劃?
Shannon Shen - Chief Financial Officer
Shannon Shen - Chief Financial Officer
Thanks, Nelson. This is Shannon.
謝謝你,Nelson。我是Shannon。
(interpreted) Our gross margin increased by 3.8 percentage points year over year and 1 percentage point quarter over quarter, an excellent result that demonstrates a clear trend of sustained improvement, particularly considering our pace of opening 11 new centers in Q2. The gross margin improvement mainly reflects our dual engine of scale and efficiency approach to center operation and management.
(口譯) 我們的毛利率年增3.8個百分點、季增1個百分點,這是非常出色的成果,清楚展現持續改善的趨勢,尤其考量到我們在第二季加速開出11家新中心。毛利率的提升主要反映我們以規模與效率雙引擎推動中心營運與管理的策略。
For the center operation, we continue to enhance per center revenue, revenue per square meter, revenue per bed and labor productivity. We raised our initial bed capacity utilization benchmark by 50%. In other words, if the original plan assumed each bed could accommodate 10 treatments per day, we have now increased that target to 15.
在中心營運方面,我們持續提升單中心營收、每平方公尺營收、每床位營收以及人力生產力。我們將初始床位產能利用率的基準提高了50%。換言之,若原先規劃假設每張床每天可承接10次療程,我們現在已將目標提高到15次。
We are restructuring our service workflows around this new benchmark to reduce customer wait times. This not only improves the user experience, but also fully unlocks the operating leverage of our centers, thereby boosting both gross margin and operating profit.
我們正依據這個新基準重整服務流程,以縮短客戶等候時間。這不僅改善使用者體驗,也能充分釋放中心的營運槓桿,進而同時提升毛利率與營業利潤。
With a maturing operating framework, mature centers take a growing share of our footprint. Ramp-up periods of our new centers are getting shorter and making positive contributions to gross margin. In Q2, 47 centers achieved center level profitability and 51 generated positive operating cash flow.
隨著營運框架日趨成熟,成熟中心在我們整體版圖中的占比持續提高。新中心的爬坡期正在縮短,並開始對毛利率做出正向貢獻。第二季有47家中心達成中心層級獲利,51家產生正向營運現金流。
For the supply chain, our expansive network give us more buying power. As our network expands, procurement cost advantage from larger volumes are being unlocked at a faster pace. With that leverage, we deepened collaborations with upstream partners to gain price competitive deal. Exclusive OEM agreements and tiered procurement contracts also gave us priority partner rights in the high-demand categories.
在供應鏈方面,我們龐大的網路帶來更強的採購議價能力。隨著網路擴張,大量採購所帶來的採購成本優勢正以更快速度釋放。憑藉這樣的槓桿,我們加深與上游夥伴的合作,以取得具價格競爭力的交易條件。獨家OEM協議與分級採購合約也讓我們在高需求品類中取得優先合作夥伴權益。
Meanwhile, the momentum of our blockbuster products proves our capability in building blockbusters while further increasing our appeal to upstream manufacturers. We will keep pushing existing blockbusters, and over the next two years, we have a robust pipeline of new products to help us improve gross margin. Meanwhile, backed by a central operations platform and AI, we can allocate resources and manage equipment, warehousing and customer operations more precisely, driving better per center economics.
同時,我們爆款產品的動能證明了我們打造爆款的能力,也進一步提升我們對上游製造商的吸引力。我們將持續推進既有爆款,並在未來兩年推出強勁的新產品管線,協助提升毛利率。此外,在中央營運平台與AI的支持下,我們能更精準地配置資源並管理設備、倉儲與客戶營運,帶動更佳的單中心經濟效益。
In short, with continued optimization of upstream costs and percent operating efficiency, we are confident about ongoing gross margin improvement. We will keep leveraging our economics of scale, deepen upstream collaboration and broaden AI adoption to drive high-quality growth.
總之,隨著上游成本持續優化以及營運效率不斷提升,我們對毛利率持續改善充滿信心。我們將持續發揮規模經濟、深化上游合作並擴大AI應用,以推動高品質成長。
Operator
Operator
Daisy Chen, Haitong.
海通證券,陳黛西。
Daisy Chen - Analyst
Daisy Chen - Analyst
(interpreted) Congratulations on the decent results with high-quality growth this quarter. My question is about our profitability. What are the core levers for the loss reduction this year? And how do you plan to move towards the group level profitability?
(口譯) 恭喜本季在高品質成長下取得不錯的成果。我的問題關於我們的獲利能力。今年減虧的核心槓桿是什麼?以及你們計畫如何邁向集團層級的獲利?
Shannon Shen - Chief Financial Officer
Shannon Shen - Chief Financial Officer
(interpreted) Thank you, Daisy. To sum up, our core lever for loss reduction this year, in one word, it is focus. We are focused on the main track of our clinic business and on profitable operations. First, from an operating portfolio perspective, our POP and injectable sales business continue to generate profits and operating cash flow. Our clinic business is in a high growth phase and remains in a strategic investment stage. This represents a well-balanced business mix.
(口譯) 謝謝你,黛西。總結來說,今年減虧的核心槓桿,用一個字概括就是「聚焦」。我們聚焦於診所業務這條主賽道,以及可獲利的營運。首先,從營運組合角度來看,我們的POP與注射類銷售業務持續貢獻利潤與營運現金流。我們的診所業務正處於高速成長階段,仍屬策略性投入期。這形成了相對均衡的業務組合。
On the one hand, we remain solid profit levels for our existing profitable business. On the other hand, we keep improving the operational efficiency of our clinic business to drive its overall profitability. Meanwhile, we scale back investment in other loss-making business through store closures, disposals and reduced capital allocation so that group resources can be increasingly focused on these two priorities.
一方面,我們維持既有獲利業務的穩健利潤水準。另一方面,我們持續提升診所業務的營運效率,以推動其整體獲利能力。同時,我們透過關店、處置以及降低資本配置,縮減對其他虧損業務的投入,使集團資源能更集中於上述兩項優先事項。
The breakeven point for our clinic is relatively clear. On our current cost base, fixed cost can be anchored based on the number and pace of new store openings. Contribution margin depends on scale growth, the rate of gross margin improvement and consumer acquisition efficiency.
我們診所業務的損益兩平點相對清晰。在目前的成本基礎上,固定成本可依新店開設的數量與節奏來錨定。貢獻毛利則取決於規模成長、毛利率改善速度以及獲客效率。
Our clinic business has maintained a high growth rate of over 30% for the past 10 quarters. Gross margins have been rising, and customer acquisition efficiency keeps improving. We expect to see substantial continued improvement in clinic gross margins in Q3 and Q4 of this year. With operating leverage kicking in, fixed costs being diluted by scaled effects plus the upcoming peak business season in autumn and winter, overall profitability for the Clinic segment is very near and achievable target.
過去10個季度,我們的診所業務維持超過30%的高速成長。毛利率持續上升,獲客效率也不斷改善。我們預期今年第三季與第四季診所毛利率仍將出現顯著且持續的改善。隨著營運槓桿開始發揮作用、固定成本被規模效應稀釋,再加上秋冬即將到來的業務旺季,診所分部的整體獲利能力已非常接近,且是可達成的目標。
Second, on cost optimization, back-office resources will also follow the same focus principle mentioned above. We will concentrate on key business and critical tasks. Through standardized operations, digital management and AI enablement, we will boost capabilities and efficiency to continuously drive cost reduction and operational improvement.
第二,在成本優化方面,後台資源也將遵循上述同樣的聚焦原則。我們將集中於關鍵業務與重要任務。透過標準化營運、數位化管理與AI賦能,我們將提升能力與效率,持續推動降本增效與營運改善。
As our footprint expands, brand awareness and consumer mind share have taken root. Referrals now account for over 50% of new customers. On top of that organic traffic, we will prioritize ROI and the core metrics to refine brand marketing investment. Taken together with continued revenue growth, operating efficiency gains and a leaner expense profile, we are confident in group level profitability going forward. Thank you.
隨著我們版圖擴張,品牌知名度與消費者心智占有率已逐步建立。轉介紹目前已占新客來源的50%以上。在這些自然流量之上,我們將以ROI與核心指標為優先,精細化品牌行銷投入。綜合持續的營收成長、營運效率提升以及更精實的費用結構,我們對未來實現集團層級獲利充滿信心。謝謝。
Operator
Operator
This concludes our question-and-answer session and today's conference call. Thank you for joining us today. You may now disconnect.
以上為問答環節以及今天的電話會議內容。感謝各位今天的參與。您現在可以掛線。
Editor
Editor
Portions of this transcript that are marked (interpreted) were spoken by an interpreter present on the live call. The interpreter was provided by the company sponsoring this event.
本逐字稿中標示為(口譯)的部分,為現場電話會議中由口譯員所說。口譯員由主辦本次活動的公司提供。